Drs. Ross Camidge and Corey Langer: How Should We Manage Acquired Resistance with a Single Lesion or More Diffuse Progression?
Drs. Ross Camidge and Corey Langer: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Drs. Ross Camidge and Corey Langer: Which New Targets and Therapies Could We Bring to the Lung Cancer Clinic in the Near Future?
Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC
ALK Rearrangements: What Are They, and Who Has Them?